ECTRIMS eLearning

Magnetic resonance imaging features in neuromielitis optica spectrum disorder according aquaporine-4 serostatus in a Colombian cohort
Author(s): ,
L.M. Giraldo
Affiliations:
Neurologia, Instituto Neurológico de Colombia
,
R.E. Llamas
Affiliations:
Neuroradiología, Universidad de Antioquia
,
C.A. Franco
Affiliations:
Neurologia, Instituto Neurológico de Colombia; Neurologia Clínica, Universidad CES
,
J.V. Tobón
Affiliations:
Neurologia, Instituto Neurológico de Colombia; Neurologia Clínica, Universidad CES
,
P.A. Mazo
Affiliations:
Neurologia, Instituto Neurológico de Colombia
,
J.L. Ascencio
Affiliations:
Neuroradiología, Instituto Neurológico de Colombia, Medellín, Colombia
M.I. Zuluaga
Affiliations:
Neurologia, Instituto Neurológico de Colombia; Neurologia Clínica, Universidad CES
ECTRIMS Learn. Giraldo Tapias L. 10/11/18; 228501; P657
Lilliana María Giraldo Tapias
Lilliana María Giraldo Tapias
Contributions
Abstract

Abstract: P657

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis

Background: Magnetic resonance imaging (MRI) findings in neuromoyelitis optica spectrum disorders (NMOSD) are crucial to support the diagnostic in seronegative patients but also to differential diagnosis.
Objective: To describe and compare MRI imaging features in brain, optic nerve and spinal cord of patients with NMOSD according the aquaporine-4 IgG (AQP4 IgG) status.
Methods: From an open single center cohort of 96 patients with NMOSD according to the 2015 international panel for NMO diagnosis, all MRI imaging available from the first episode were evaluated and compared according AQP4 IgG status among groups.
Results: 38 patients had MRI available from the first episode, 28 (73.4%) AQP4 (+) and 10 (26.3%) AQP4(-)/no data (ND). The median age at first episode was 43 (IQR 34-58) years. Optic neuritis (ON) was the most common presentation in the first episode 17 (44.7%). 36 patients had brain MRI, 23 (63.9%) were abnormal with no differences according serostatus [66% AQP4 (+) and 55% AQP4(-)/ND p=0.69]; the more frequent finding were unspecific supratentorial white matter lesions [44% AQP4 (+) and 22% AQP4(-)/ND p=0.21]. 36 patients had optic nerve images, 28 were abnormal, more frequently with unilateral ON [48% AQP4 (+) and 66% AQP4(-)/ND p=0.56] compromising the posterior segment of the optic nerve in the 61% [51% AQP4 (+) and 88% AQP4(-)/ND p=0.12] with edema [70% AQP4 (+) and 77% AQP4(-)/ND p=0.50] and gadolinium enhancement [66% AQP4 (+) and 55% AQP4(-)/ND p=0.13]. Regarding spinal cord MRI the more common findings were longitudinally extensive myelitis in 60% of the patients with a median of 7 (IQR 4-7) segments, more frequently involving the central portion of the spinal cord [cervical 29% AQP4 (+) and 37% AQP4(-)/ND p=0.91; thoracic 66% AQP4 (+) and 14% AQP4(-)/ND p=0.63] with more than 50% of the transverse area of the cord involved [cervical 35% AQP4 (+) and 50% AQP4(-)/ND p=0.65; thoracic 53% AQP4 (+) and 28% AQP4(-)/ND p=0.37].
Conclusion: We did not find differences in the MRI fetaures in NMOSD patients compared according AQP4 IgG serostatus.
Disclosure: Lilliana M Giraldo, nothing to discloseRafael E Llamas, nothing to disclose
Cesar A Franco, nothing to disclose
José Vladimir Tobón, nothing to disclose
Paula Andrea Mazo, nothing to disclose
José L Ascencio, nothing to disclose
María I Zuluaga, nothing to disclose

Abstract: P657

Type: Poster Sessions

Abstract Category: Clinical aspects of MS - Diagnosis and differential diagnosis

Background: Magnetic resonance imaging (MRI) findings in neuromoyelitis optica spectrum disorders (NMOSD) are crucial to support the diagnostic in seronegative patients but also to differential diagnosis.
Objective: To describe and compare MRI imaging features in brain, optic nerve and spinal cord of patients with NMOSD according the aquaporine-4 IgG (AQP4 IgG) status.
Methods: From an open single center cohort of 96 patients with NMOSD according to the 2015 international panel for NMO diagnosis, all MRI imaging available from the first episode were evaluated and compared according AQP4 IgG status among groups.
Results: 38 patients had MRI available from the first episode, 28 (73.4%) AQP4 (+) and 10 (26.3%) AQP4(-)/no data (ND). The median age at first episode was 43 (IQR 34-58) years. Optic neuritis (ON) was the most common presentation in the first episode 17 (44.7%). 36 patients had brain MRI, 23 (63.9%) were abnormal with no differences according serostatus [66% AQP4 (+) and 55% AQP4(-)/ND p=0.69]; the more frequent finding were unspecific supratentorial white matter lesions [44% AQP4 (+) and 22% AQP4(-)/ND p=0.21]. 36 patients had optic nerve images, 28 were abnormal, more frequently with unilateral ON [48% AQP4 (+) and 66% AQP4(-)/ND p=0.56] compromising the posterior segment of the optic nerve in the 61% [51% AQP4 (+) and 88% AQP4(-)/ND p=0.12] with edema [70% AQP4 (+) and 77% AQP4(-)/ND p=0.50] and gadolinium enhancement [66% AQP4 (+) and 55% AQP4(-)/ND p=0.13]. Regarding spinal cord MRI the more common findings were longitudinally extensive myelitis in 60% of the patients with a median of 7 (IQR 4-7) segments, more frequently involving the central portion of the spinal cord [cervical 29% AQP4 (+) and 37% AQP4(-)/ND p=0.91; thoracic 66% AQP4 (+) and 14% AQP4(-)/ND p=0.63] with more than 50% of the transverse area of the cord involved [cervical 35% AQP4 (+) and 50% AQP4(-)/ND p=0.65; thoracic 53% AQP4 (+) and 28% AQP4(-)/ND p=0.37].
Conclusion: We did not find differences in the MRI fetaures in NMOSD patients compared according AQP4 IgG serostatus.
Disclosure: Lilliana M Giraldo, nothing to discloseRafael E Llamas, nothing to disclose
Cesar A Franco, nothing to disclose
José Vladimir Tobón, nothing to disclose
Paula Andrea Mazo, nothing to disclose
José L Ascencio, nothing to disclose
María I Zuluaga, nothing to disclose

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies